Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus chemotherapy in advanced NSCLC with primary resistance to PD-1/PD-L1 inhibitors
NCT03041181Phase 2Terminated
- Start
- Jan 2017
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC). Started Jan 2017; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03041181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041181.